Exceptional long term response to crizotinib in ROS 1-postive advanced non small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer globally.
• A subset of NSCLC patients present with actionable oncogenic alterations, including ROS1 rearrangements.
• Identifying these alterations is crucial for effective treatment strategies.

Observation:

• A 52-year-old male patient with advanced NSCLC was diagnosed with a ROS1 fusion gene.
• Initial treatment with conventional chemotherapy yielded a poor response.
• The patient subsequently received crizotinib, a targeted therapy.

Findings:

• The patient demonstrated an exceptional and durable response to crizotinib.
• Progression-free survival exceeded 94 months.
• A complete metabolic response was confirmed by PET scan.

Implications:

• This case highlights the critical role of molecular profiling in NSCLC treatment selection.
• Targeted therapy with crizotinib is highly effective in ROS1-positive NSCLC patients.
• Long-term outcomes are achievable with personalized medicine approaches.